A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-a) inhibitors, adalimumab and infliximab, for Crohn's disease

Dretzke J, Edlin R, Round J, Connock M, Hulme C, Czeczot J, Fry-Smith A, McCabe C, Meads C
Record ID 32007000900
English
Authors' objectives:

The objectives of this Technology Assessment Report (TAR) were:

•To update a previous TAR on the effectiveness and cost-effectiveness of infliximab in adults with moderate-to-severe CD or fistulising CD who are refractory to or intolerant of conventional treatment.
•To review the evidence on the clinical effectiveness and cost-effectiveness of infliximab in children with moderate-to-severe CD who are refractory to or intolerant of conventional treatment.
•To review the evidence on the clinical effectiveness and cost-effectiveness of a further anti-TNF-α antibody, adalimumab, in adults with moderate-to-severe CD who are refractory to or intolerant of conventional treatment.
•To investigate whether there is evidence for greater clinical effectiveness or cost-effectiveness for either adalimumab or infliximab.

Authors' recommendations: The systematic review and economic evaluation found that both adalimumab and infliximab are likely to be considered cost-effective (dominant relative to standard care) as induction therapy in the treatment of severe Crohn’s disease (CD), and adalimumab (but not infliximab) is cost-effective for moderate CD, according to limits generally accepted by the National Institute for Health and Clinical Excellence. Neither drug is likely to be cost-effective as longer term maintenance therapy for moderate or severe disease.
Details
Project Status: Completed
URL for project: http://www.hta.ac.uk/1652
Year Published: 2011
URL for published report: n/a
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Cost-Benefit Analysis
  • Practice Guideline
  • Treatment Outcome
  • Crohn Disease
  • Tumor Necrosis Factor-alpha
  • Adalimumab
  • Infliximab
  • Antibodies, Monoclonal, Humanized
Contact
Organisation Name: NIHR Health Technology Assessment programme
Contact Address: NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name: journals.library@nihr.ac.uk
Contact Email: journals.library@nihr.ac.uk
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.